The Ramco Cements and Cadila Healthcare on Friday announced their fourth quarter (Q4) earnings that ended on March 31, 2020. While the Ramco groups reported a decline of 13.17 per cent in its consolidated total profit at Rs 142.90 crore for the fourth quarter. While Cadila Healthcare’s Q4 performance was marginally better than the estimations made by the brokerages.
Ramco’s decline in the net profit was mainly due to the coronavirus-induced lockdown.
Earlier, during the January-March quarter of 2018-19, the company had recorded a net profit of Rs 164.58 crore, the company said in a regulatory filing.
During the quarter under review, Ramco’s total revenue was down with 9.17 per cent to Rs 1,403.90 crore as against Rs 1,545.77 crore during the same quarter of the in the previous fiscal.
Because of the nationwide lockdown declared by the central and state governments to curb the coronavirus pandemic during the second half of the March month 2020, the company’s operations at all of its locations were severely affected, the company said.
However, for fiscal 2019-20, The Ramco Cements’ net profit stood up with 18.43 per cent to Rs 605.70 crore. And the Total revenue collection in FY20 stood at Rs 5,422.80 crore, up with 4.53 per cent. It was Rs 5,187.30 crore in 2019.
Coming to the net earning Cadila Healthcare in Q4, overall, the company performed well than expected. The performance was driven by higher US sales and better gross margin. However, in India, the revenue collection stood below than its estimations, mainly impacted by the coronavirus outbreak and related disruptions.
Total revenue remained unmoved at Rs 37.3 billion, EBITDA margin dropped 90bps to 20.5 per cent as compared to the brokerage estimate of 18.7 per cent and adjusted PAT declined by 8.1 per cent to stand at Rs 4.2 billion against brokerage estimate of Rs 3.7 billion. For EBITDA margin beat of 180bps factors remain the same, a higher gross margin in US business and controlled gross margin.